Aktiv entered into a development agreement with a global pharma company to co-develop a high-concentration, large-dose injection using its PenPal® platform. BROOMFIELD, CO, UNITED STATES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback